Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors. [electronic resource]
Producer: 20180209Description: 233-238 p. digitalISSN:- 1308-5263
- Aged
- Aged, 80 and over
- Bendamustine Hydrochloride -- administration & dosage
- Disease-Free Survival
- Drug Resistance, Neoplasm -- drug effects
- Female
- Humans
- Male
- Middle Aged
- Multiple Myeloma -- drug therapy
- Proteasome Inhibitors -- administration & dosage
- Recurrence
- Retrospective Studies
- Survival Rate
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.